Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection-Reference-Cited by-同舟云学术

Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kim Lee-Han¹²^ORCID,Kang Soon Myung¹³,Whang Jake⁴^ORCID,Kwon Kee Woong¹³^ORCID,Shin Sung Jae¹²³^ORCID

Affiliation:

1. Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea

2. Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, South Korea

3. Brain Korea 21 Project for Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, South Korea

4. Korea Mycobacterium Resource Center (KMRC) & Basic Research Section, The Korean Institute of Tuberculosis (KIT), Cheongju-si, Chungcheongbuk-do, South Korea

Abstract

Accumulating evidence suggests that drug repurposing has drawn attention as an anticipative strategy for controlling tuberculosis (TB), considering the dwindling drug discovery and development pipeline. In this study, we explored the antigout drug febuxostat and evaluated its antibacterial activity against Mycobacterium species.

Funder

National Research Foundation of Korea

Korea Health Industry Development Institute

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00762-22

Reference53 articles.

1. World Health Organization. Global tuberculosis report 2020. World Health Organization Geneva Switzerland.

2. Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

3. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

4. Challenges in tuberculosis drug research and development

5. Drug-resistant TB: deadly, costly and in need of a vaccine

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility of eliminating tuberculosis by shortening the diagnostic delay: A retrospective analysis and modelling study in China during the pre-COVID-19 era;Heliyon;2024-08